Back to Search

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

  • Protocol Number: 202211181
  • Principal Investigator: Chapman, Will
  • Cancer Types: Gastrointestinal

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.

Protocol Interventions

Durvalumab, Tremelimumab, Liver Transplant